In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans
- PMID: 7486902
- PMCID: PMC162809
- DOI: 10.1128/AAC.39.8.1691
In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans
Abstract
Amphotericin B and fluconazole are current acceptable therapies for cryptococcal meningitis; however, their effect remains suboptimal. The combination of fluconazole and flucytosine has yielded encouraging clinical results in human immunodeficiency virus patients with cryptococcal meningitis. To investigate the biological basis of this finding, we performed in vitro combination testing of fluconazole and flucytosine against 50 clinical strains of Cryptococcus neoformans var. neoformans. Synergy (fractional inhibitory concentration index of < 1.0) was observed in 62% of cases, while antagonism (fractional inhibitory concentration index of > 2.0) was not observed. For cases in which synergy was not achieved (autonomous or additive effects), the beneficial effect of the combination was still seen (i.e., there was still a decrease, although not as dramatic, in the MIC of one or both drugs when used in combination). The in vitro inhibitory action of flucytosine was greatly enhanced by the addition of fluconazole; the flucytosine MICs for Cryptococcus isolates were markedly decreased to concentrations which were severalfold lower than the achievable cerebrospinal fluid flucytosine concentration. On the other hand, the addition of flucytosine did not greatly enhance the in vitro activity of fluconazole if the initial fluconazole MIC for the isolate was > or = 8 micrograms/ml. Controlled clinical studies are warranted to further elucidate the potential utility of fluconazole-flucytosine combination therapy.
Similar articles
-
Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.Antimicrob Agents Chemother. 1997 Feb;41(2):331-6. doi: 10.1128/AAC.41.2.331. Antimicrob Agents Chemother. 1997. PMID: 9021188 Free PMC article.
-
Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.Diagn Microbiol Infect Dis. 1998 Nov;32(3):191-9. doi: 10.1016/s0732-8893(98)00095-9. Diagn Microbiol Infect Dis. 1998. PMID: 9884835
-
The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans.Mycoses. 2019 Sep;62(9):818-825. doi: 10.1111/myc.12955. Epub 2019 Jun 23. Mycoses. 2019. PMID: 31173410 Free PMC article.
-
Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings.Cochrane Database Syst Rev. 2008 Oct 8;(4):CD005647. doi: 10.1002/14651858.CD005647.pub2. Cochrane Database Syst Rev. 2008. Update in: Cochrane Database Syst Rev. 2018 Jul 25;7:CD005647. doi: 10.1002/14651858.CD005647.pub3 PMID: 18843697 Updated. Review.
-
Searching for new antifungals for the treatment of cryptococcosis.Rev Soc Bras Med Trop. 2023 Jul 24;56:e01212023. doi: 10.1590/0037-8682-0121-2023. eCollection 2023. Rev Soc Bras Med Trop. 2023. PMID: 37493736 Free PMC article. Review.
Cited by
-
In vitro antifungal combination of flucytosine with amphotericin B, voriconazole, or micafungin against Candida auris shows no antagonism.Antimicrob Agents Chemother. 2019 Sep 9;63(12):e01393-19. doi: 10.1128/AAC.01393-19. Epub 2019 Oct 7. Antimicrob Agents Chemother. 2019. PMID: 31591129 Free PMC article.
-
Combination treatment of invasive fungal infections.Clin Microbiol Rev. 2005 Jan;18(1):163-94. doi: 10.1128/CMR.18.1.163-194.2005. Clin Microbiol Rev. 2005. PMID: 15653825 Free PMC article. Review.
-
Molecular epidemiology and antifungal susceptibility profiles of clinical Cryptococcus neoformans/Cryptococcus gattii species complex.J Med Microbiol. 2020 Jan;69(1):72-81. doi: 10.1099/jmm.0.001101. J Med Microbiol. 2020. PMID: 31750814 Free PMC article.
-
In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles.Antimicrob Agents Chemother. 1997 Aug;41(8):1812-4. doi: 10.1128/AAC.41.8.1812. Antimicrob Agents Chemother. 1997. PMID: 9257768 Free PMC article.
-
Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.Antimicrob Agents Chemother. 1997 Feb;41(2):331-6. doi: 10.1128/AAC.41.2.331. Antimicrob Agents Chemother. 1997. PMID: 9021188 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources